{"id":52681,"date":"2023-01-09T13:02:11","date_gmt":"2023-01-09T12:02:11","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/opticyte-earns-fda-breakthrough-device-designation-for-the-first-cell-o2-patient-monitor-for-organ-failure\/"},"modified":"2023-01-09T13:02:11","modified_gmt":"2023-01-09T12:02:11","slug":"opticyte-earns-fda-breakthrough-device-designation-for-the-first-cell-o2-patient-monitor-for-organ-failure","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/opticyte-earns-fda-breakthrough-device-designation-for-the-first-cell-o2-patient-monitor-for-organ-failure\/","title":{"rendered":"Opticyte Earns FDA Breakthrough Device Designation for the First Cell O2 Patient Monitor for Organ Failure"},"content":{"rendered":"
\n

\nOpticyte leverages proprietary machine learning to noninvasively assess organ dysfunction due to low cellular oxygenation in patients of all skin tones<\/i>\n<\/p>\n

SEATTLE–(BUSINESS WIRE)–Opticyte<\/a>, a medical device start-up, announced today that its Cell O\u2082 Patient Monitor received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for real-time, continuous monitoring of patients at risk of organ failure.\n<\/p>\n

<\/a><\/p>\n

\nThe Cell O\u2082 Patient Monitor uses noninvasive optical spectroscopy technology to measure and detect systemic low oxygen levels inside cells. The device holds promise to reduce organ failure by immediate and continuous monitoring of cellular oxygen levels during hospitalization for sepsis, trauma, and myocardial infarction.\n<\/p>\n

\nThe Breakthrough Device Designation provides for timely interactions with the FDA and prioritized review of the regulatory submissions. The program is designed to help accelerate the regulatory approval process for devices with the potential to provide more effective treatment over existing standard of care for life-threatening diseases and enables patients to achieve more timely access to emerging medical devices. Fewer than 800 devices in the history of the FDA regulatory approval process have ever received Breakthrough Device Designation.\n<\/p>\n

\n\u201cWe\u2019re pleased the FDA recognized the strength of our data and the promise of our technology to deliver reliable and actionable cellular oxygenation readings for medical staff\u2013often working in emergency medicine\u2013to more effectively prevent organ failure and save lives,\u201d said Lori Arakaki, Ph.D., Opticyte Co-Founder and CEO. \u201cThis new designation will allow us to more quickly reach sepsis, trauma, and cardiac surgery patients with organ dysfunction who are on the verge of organ failure.\u201d\n<\/p>\n

\nThe Opticyte device was used in a recently completed first-in-human observational study of nearly 150 patients at Harborview Medical Center and University of Washington Medical Center in Seattle. The study documented real-time readings of low cell O\u2082 <\/sub>in patients with sepsis, a potential precursor to organ failure, shock, and death. Opticyte is currently coordinating additional studies investigating the prognostic value of cell oxygenation for organ dysfunction and mortality in patients across indications and care settings.\n<\/p>\n

\nAccording to the Centers for Disease Control and Prevention (CDC), at least 1.7 million adults in the U.S. develop sepsis, and nearly 270,000 die as a result every year. The current standard of care for determining organ dysfunction, including for patients with sepsis, trauma or myocardial infarction, requires a blood draw, lab work, and approximately two hours of testing time. The significant market gap in the United States for these three populations across emergency and intensive care represents a $2.8B opportunity annually.\n<\/p>\n

\n\u201cIn the emergency department, we\u2019re always racing against time. Opticyte\u2019s technology offers the potential to see continuous, real-time data indicating systemic low cellular oxygenation and allow those of us on the frontlines of care to respond with effective countermeasures to course correct potential organ dysfunction and ideally save more lives,\u201d said Dr. Eileen Bulger, Chief of Trauma at Harborview Medical Center.\n<\/p>\n

\nOpticyte studied more than 130 healthy people with a wide variety of physical characteristics, including lighter and darker skin tones, to develop the training and testing data for its machine learning algorithm.\n<\/p>\n

\n\u201cOpticyte\u2019s commitment to ensuring people with different skin tones and pigmentation are included in the foundation of their technology, dramatically improving the standard of care and saving lives for the hundreds of thousands of people suffering from organ dysfunction, makes us especially proud to support their efforts,\u201d said Nate Doran, a Seattle-based micro VC.\n<\/p>\n

\nThe Opticyte team will be attending JP Morgan Healthcare Conference<\/a> and presenting at the RESI Conference<\/a> in San Francisco the week of January 9, 2023.\n<\/p>\n

\nFollow Opticyte on Twitter<\/a> and LinkedIn<\/a> for the latest news and information.\n<\/p>\n

\nABOUT OPTICYTE<\/b>\n<\/p>\n

\nOpticyte, Inc., founded in 2016, is a spinoff from the University of Washington and is headquartered in Seattle, WA. Opticyte is transforming the standard of care for the leading causes of organ failure, including sepsis, with real-time cell oxygenation measurement. With Opticyte\u2019s Cell O\u2082 Patient Monitor, clinicians can immediately respond to a patient\u2019s urgent medical condition with confidence to prevent irreversible organ damage and failure.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nEric Schudiske
\n
eric@s2spr.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Opticyte leverages proprietary machine learning to noninvasively assess organ dysfunction due to low cellular oxygenation in patients of all skin tones SEATTLE–(BUSINESS WIRE)–Opticyte, a medical device start-up, announced today that its Cell O\u2082 Patient Monitor received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for real-time, continuous monitoring of patients at risk … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52681","6":"format-standard","7":"category-industry"},"yoast_head":"\nOpticyte Earns FDA Breakthrough Device Designation for the First Cell O2 Patient Monitor for Organ Failure - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/opticyte-earns-fda-breakthrough-device-designation-for-the-first-cell-o2-patient-monitor-for-organ-failure\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Opticyte Earns FDA Breakthrough Device Designation for the First Cell O2 Patient Monitor for Organ Failure - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Opticyte leverages proprietary machine learning to noninvasively assess organ dysfunction due to low cellular oxygenation in patients of all skin tones SEATTLE–(BUSINESS WIRE)–Opticyte, a medical device start-up, announced today that its Cell O\u2082 Patient Monitor received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for real-time, continuous monitoring of patients at risk ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/opticyte-earns-fda-breakthrough-device-designation-for-the-first-cell-o2-patient-monitor-for-organ-failure\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-09T12:02:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230109005154\/en\/1679657\/21\/Opticyte_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/opticyte-earns-fda-breakthrough-device-designation-for-the-first-cell-o2-patient-monitor-for-organ-failure\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/opticyte-earns-fda-breakthrough-device-designation-for-the-first-cell-o2-patient-monitor-for-organ-failure\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Opticyte Earns FDA Breakthrough Device Designation for the First Cell O2 Patient Monitor for Organ Failure\",\"datePublished\":\"2023-01-09T12:02:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/opticyte-earns-fda-breakthrough-device-designation-for-the-first-cell-o2-patient-monitor-for-organ-failure\\\/\"},\"wordCount\":691,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/opticyte-earns-fda-breakthrough-device-designation-for-the-first-cell-o2-patient-monitor-for-organ-failure\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230109005154\\\/en\\\/1679657\\\/21\\\/Opticyte_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/opticyte-earns-fda-breakthrough-device-designation-for-the-first-cell-o2-patient-monitor-for-organ-failure\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/opticyte-earns-fda-breakthrough-device-designation-for-the-first-cell-o2-patient-monitor-for-organ-failure\\\/\",\"name\":\"Opticyte Earns FDA Breakthrough Device Designation for the First Cell O2 Patient Monitor for Organ Failure - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/opticyte-earns-fda-breakthrough-device-designation-for-the-first-cell-o2-patient-monitor-for-organ-failure\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/opticyte-earns-fda-breakthrough-device-designation-for-the-first-cell-o2-patient-monitor-for-organ-failure\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230109005154\\\/en\\\/1679657\\\/21\\\/Opticyte_Logo.jpg\",\"datePublished\":\"2023-01-09T12:02:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/opticyte-earns-fda-breakthrough-device-designation-for-the-first-cell-o2-patient-monitor-for-organ-failure\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/opticyte-earns-fda-breakthrough-device-designation-for-the-first-cell-o2-patient-monitor-for-organ-failure\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/opticyte-earns-fda-breakthrough-device-designation-for-the-first-cell-o2-patient-monitor-for-organ-failure\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230109005154\\\/en\\\/1679657\\\/21\\\/Opticyte_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230109005154\\\/en\\\/1679657\\\/21\\\/Opticyte_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/opticyte-earns-fda-breakthrough-device-designation-for-the-first-cell-o2-patient-monitor-for-organ-failure\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Opticyte Earns FDA Breakthrough Device Designation for the First Cell O2 Patient Monitor for Organ Failure\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Opticyte Earns FDA Breakthrough Device Designation for the First Cell O2 Patient Monitor for Organ Failure - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/opticyte-earns-fda-breakthrough-device-designation-for-the-first-cell-o2-patient-monitor-for-organ-failure\/","og_locale":"en_US","og_type":"article","og_title":"Opticyte Earns FDA Breakthrough Device Designation for the First Cell O2 Patient Monitor for Organ Failure - Pharma Trend","og_description":"Opticyte leverages proprietary machine learning to noninvasively assess organ dysfunction due to low cellular oxygenation in patients of all skin tones SEATTLE–(BUSINESS WIRE)–Opticyte, a medical device start-up, announced today that its Cell O\u2082 Patient Monitor received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for real-time, continuous monitoring of patients at risk ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/opticyte-earns-fda-breakthrough-device-designation-for-the-first-cell-o2-patient-monitor-for-organ-failure\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-09T12:02:11+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230109005154\/en\/1679657\/21\/Opticyte_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/opticyte-earns-fda-breakthrough-device-designation-for-the-first-cell-o2-patient-monitor-for-organ-failure\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/opticyte-earns-fda-breakthrough-device-designation-for-the-first-cell-o2-patient-monitor-for-organ-failure\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Opticyte Earns FDA Breakthrough Device Designation for the First Cell O2 Patient Monitor for Organ Failure","datePublished":"2023-01-09T12:02:11+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/opticyte-earns-fda-breakthrough-device-designation-for-the-first-cell-o2-patient-monitor-for-organ-failure\/"},"wordCount":691,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/opticyte-earns-fda-breakthrough-device-designation-for-the-first-cell-o2-patient-monitor-for-organ-failure\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230109005154\/en\/1679657\/21\/Opticyte_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/opticyte-earns-fda-breakthrough-device-designation-for-the-first-cell-o2-patient-monitor-for-organ-failure\/","url":"https:\/\/pharma-trend.com\/en\/opticyte-earns-fda-breakthrough-device-designation-for-the-first-cell-o2-patient-monitor-for-organ-failure\/","name":"Opticyte Earns FDA Breakthrough Device Designation for the First Cell O2 Patient Monitor for Organ Failure - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/opticyte-earns-fda-breakthrough-device-designation-for-the-first-cell-o2-patient-monitor-for-organ-failure\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/opticyte-earns-fda-breakthrough-device-designation-for-the-first-cell-o2-patient-monitor-for-organ-failure\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230109005154\/en\/1679657\/21\/Opticyte_Logo.jpg","datePublished":"2023-01-09T12:02:11+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/opticyte-earns-fda-breakthrough-device-designation-for-the-first-cell-o2-patient-monitor-for-organ-failure\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/opticyte-earns-fda-breakthrough-device-designation-for-the-first-cell-o2-patient-monitor-for-organ-failure\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/opticyte-earns-fda-breakthrough-device-designation-for-the-first-cell-o2-patient-monitor-for-organ-failure\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230109005154\/en\/1679657\/21\/Opticyte_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230109005154\/en\/1679657\/21\/Opticyte_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/opticyte-earns-fda-breakthrough-device-designation-for-the-first-cell-o2-patient-monitor-for-organ-failure\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Opticyte Earns FDA Breakthrough Device Designation for the First Cell O2 Patient Monitor for Organ Failure"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52681","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52681"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52681\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52681"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52681"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52681"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}